Celularity (CELU) Revenue & Revenue Breakdown
Celularity Revenue Highlights
Latest Revenue (Y)
$22.77M
Latest Revenue (Q)
$18.13M
Main Segment (Y)
Product
Celularity Revenue by Period
Celularity Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $22.77M | 26.68% |
| 2022-12-31 | $17.98M | -15.75% |
| 2021-12-31 | $21.34M | 49.43% |
| 2020-12-31 | $14.28M | -32.48% |
| 2019-12-31 | $21.15M | 20.47% |
| 2018-12-31 | $17.55M | - |
Celularity generated $22.77M in revenue during NA 2023, up 26.68% compared to the previous quarter, and up 129.72% compared to the same period a year ago.
Celularity Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $18.13M | 95.05% |
| 2024-09-30 | $9.30M | -23.24% |
| 2024-06-30 | $12.11M | -17.51% |
| 2024-03-31 | $14.68M | 21.21% |
| 2023-12-31 | $12.11M | 219.92% |
| 2023-09-30 | $3.79M | 28.86% |
| 2023-06-30 | $2.94M | -25.34% |
| 2023-03-31 | $3.94M | -4.70% |
| 2022-12-31 | $4.13M | -0.15% |
| 2022-09-30 | $4.13M | 9.51% |
| 2022-06-30 | $3.78M | -36.38% |
| 2022-03-31 | $5.93M | 22.19% |
| 2021-12-31 | $4.86M | -54.27% |
| 2021-09-30 | $10.62M | 232.25% |
| 2021-06-30 | $3.20M | 20.19% |
| 2021-03-31 | $2.66M | -17.98% |
| 2020-12-31 | $3.24M | -3.34% |
| 2020-09-30 | $3.35M | -3.37% |
| 2020-06-30 | $3.47M | -17.49% |
| 2020-03-31 | $4.21M | -18.31% |
| 2019-12-31 | $5.15M | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Celularity generated $18.13M in revenue during Q4 2024, up 95.05% compared to the previous quarter, and up 478.92% compared to the same period a year ago.
Celularity Revenue Breakdown
Celularity Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| License Royalty and Other | $13.74M | - | - | - |
| Service | $5.14M | $5.44M | $5.51M | $5.52M |
| Product | $35.34M | $13.15M | $3.75M | $3.80M |
| License Royalty And Other | - | $5.74M | $8.71M | $12.01M |
Celularity's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (65.17%), License Royalty and Other (25.35%), and Service (9.48%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | $1.27M | $1.28M | $1.29M | $1.28M | $1.29M | $5.04M | $398.00K | $1.45M | $899.00K | $1.37M | $1.28M | $1.32M | $1.34M |
| License, Royalty and Other | $2.47M | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $2.55M | $9.14M | $3.39M | $9.96M | $12.84M | $12.59M | $557.00K | $829.00K | $812.00K | $1.23M | $651.00K | $1.07M | $849.00K |
| License Royalty And Other | - | - | $4.61M | $870.00K | $551.00K | $3.09M | $2.65M | $1.85M | $5.50M | $1.18M | $4.00M | $2.47M | $8.43M |
Celularity's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product (40.50%), License, Royalty and Other (39.26%), and Service (20.25%).
Celularity Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|
| License Royalty And Other | $1.85M | $5.50M | $1.18M | $4.00M | $2.47M | $8.43M |
| Service | $1.45M | $899.00K | $1.37M | $1.28M | $1.32M | $1.34M |
| Product | $829.00K | $812.00K | $1.23M | $651.00K | $1.07M | $849.00K |
Celularity's latest quarterly revenue breakdown by geography, as of Dec 22: License Royalty And Other (44.78%), Service (35.14%), and Product (20.08%).
Celularity Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics | $145.24M | $37.93M |
| MRSN | Mersana Therapeutics | $40.50M | $3.06M |
| CELU | Celularity | $22.77M | $18.13M |
| BRNS | Barinthus Biotherapeutics | $14.97M | - |
| BTAI | BioXcel Therapeutics | $2.27M | $120.00K |
| EVAX | Evaxion Biotech | $73.11K | $50.88K |
| INMB | INmune Bio | $14.00K | $50.00K |
| BCAB | BioAtla | - | - |
| SNTI | Senti Biosciences | - | - |
| TPST | Tempest Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |